ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ClearPoint Neuro, Inc.NASDAQ: CLPT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.05M, compared with -$5.67M a year earlier. Trailing-twelve-month EBITDA was -$23.66M.
Context
- EBITDA amounted to 56.4% of revenue in FY2025, up 2.2 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$30.26M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the -22.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.05M-13.2% QoQ
- Last fiscal yearDec 2025
- -$20.86M-22.6% YoY
- LTMMar 2026
- -$23.66M-24.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -24.2% | -19.4% | +4.9 pp |
| 1 year | -22.6% | -45.0% | -22.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (20.86M) USD
- Year-over-year change
- -22.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (20.86M) | -22.6% |
| FY2024 | 2024-12-31 | (17.01M) | +17.6% |
| FY2023 | 2023-12-31 | (20.63M) | -32.5% |
| FY2022 | 2022-12-31 | (15.58M) | -22.2% |
| FY2021 | 2021-12-31 | (12.75M) | — |
EBITDA vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.4% is the 6th highest of 10, against a peer median of +5.7%.
- EBITDA amounts to 58.2% of revenue for CLPT, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.51M USD | +693.8% | — | 11.5% | |
| LTM Mar 2026 | CA$49.42M CAD | +201.3% | — | 5.3% | |
| LTM Mar 2026 | -$5.76M USD | -220.1% | +92.3% | 2.5% | |
| LTM Mar 2026 | -$5.99M USD | +68.1% | — | 2.9% | |
| LTM Apr 2026 | -$6.2M USD | -108.2% | -68.7% | 0.7% | |
| LTM Mar 2026 | -$21.6M USD | +93.7% | — | 3.0% | |
| LTM Mar 2026 | -$22.15M USD | -84.1% | — | 10.8% | |
| LTM Mar 2026 | -$23.66M USD | -24.4% | — | 58.2% | |
| LTM Mar 2026 | -$81.51M USD | +5.7% | — | 94.5% | |
| LTM Mar 2026 | -$176.6M USD | -34.4% | — | — | |
| Peer median (excluding CLPT) | — | +5.7% | +11.8% | 4.1% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.